Observational studyJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2015
Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia.
Observational study in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03312075 (Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.), which is not on this map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.The Cochrane database of systematic reviews · 2025Pooled it
- Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.The Cochrane database of systematic reviews · 2016Pooled it
- Guideline
- Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria--experiences from the Danish Cystic Fibrosis cohort study.BMC infectious diseases · 2014Trial
- The Epidemiology of Nontuberculous Mycobacteria in Cystic Fibrosis.Children (Basel, Switzerland) · 2025Review
- Epidemiology, microbiology and clinical impacts of non-tuberculous mycobacteria in adult patients with cystic fibrosis.Heliyon · 2025Article
- Growing from common ground: nontuberculous mycobacteria and bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Mycobacterium abscessus extracellular vesicles increase mycobacterial resistance to clarithromycin in vitro.Proteomics · 2024Article
- Sources, transmission and hospital-associated outbreaks of nontuberculous mycobacteria: a review.Future microbiology · 2024Review
- A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2023Article
- Molecular Identification of Strains within thePolish journal of microbiology · 2023Article
- Real-World Data Collection from Expanded Access Case Studies for the Treatment of Nontuberculous Mycobacterial Infection with Clofazimine.medRxiv : the preprint server for health sciences · 2023Article
- Molecular Epidemiology of Mycobacterium abscessus Isolates Recovered from German Cystic Fibrosis Patients.Microbiology spectrum · 2022Article
- Genetic and hormonal mechanisms underlying sex-specific immune responses in tuberculosis.Trends in immunology · 2022Review
- Article
- Adaptive Immune Response toFrontiers in cellular and infection microbiology · 2022Article
- Virulence Mechanisms ofFrontiers in microbiology · 2022Review
- Non-tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade-off and NTM ways into virulence.Scandinavian journal of immunology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
backgroundNontuberculous mycobacteria (NTM) are an emerging threat to cystic fibrosis (CF) patients but their epidemiology is not well described.
methodsIn this retrospective observational study we identified all Scandinavian CF patients with a positive NTM culture from airway secretions from 2000 to the end of 2012 and used national CF databases to describe microbiological and clinical characteristics.
resultsDuring the 13-year period 157 (11%) CF patients were culture positive for NTM at least once. Mycobacterium abscessus complex (MABSC) (45%) and Mycobacterium avium complex (MAC) (32%) were the predominant species with geographical differences in distribution. Younger patients were more prone to MABSC (p<0.01). Despite treatment, less than one-third of MABSC patients with repeated positive cultures cleared their infection and a quarter had a lung transplant or died.
conclusionNTM are significant CF pathogens and are becoming more prevalent in Scandinavia. MABSC and MAC appear to target distinct patient groups. Having multiple positive cultures despite treatment conveys a poor outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.